Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

prnasiaNovember 24, 2020

Tag: 3SBio , SEL-212 , Selecta

PharmaSources Customer Service